UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Newsroom

    Spotlight Story

    UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

    Read more

    Press Releases

    Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by…

    Read More

    UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

    Read More

    BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of…

    Read More

    UCB presents latest research across leading neurology portfolio at American Academy of Neurology (…

    Read More

    New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular…

    Read More

    Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and…

    Read More

    UCB Stories

    UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

    Read More

    UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial…

    Read More

    Tu Salud Tu Familia Generates Awareness for Rare Diseases such as Myasthenia Gravis

    Read More

    Resources for Resilience: Dravet Syndrome Awareness Month for Families Living with DEEs

    Read More

    Partnering with Patient Communities to Advance HS Awareness and Care

    Read More

    Recognizing Myasthenia Gravis Month – The Importance of Addressing Unmet Patient Needs

    Read More

    For More Information